RCKT

ROCKET PHARMACEUTICALS, INC. RCKT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$0

Quarter to Jun 30

Net income

$123.21M

Quarter to Jun 30

Free cash flow

$-39.62M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$340.99M total
RTW INVESTMENTS, LP
$60.49M0.0%
BlackRock, Inc.
$33.94M+26.7%
VANGUARD PORTFOLIO MANAGEMENT LLC
$19.87M+23.9%
CITIGROUP INC
$16.64M-4.7%
MARSHALL WACE, LLP
$13.78M+32.6%
MILLENNIUM MANAGEMENT LLC
$13.68M+28.3%
Newtyn Management, LLC
$13.68M+26.3%
MAVERICK CAPITAL LTD
$13.42M+10.0%
VANGUARD CAPITAL MANAGEMENT LLC
$12.94M+0.2%
AQR CAPITAL MANAGEMENT LLC
$11.58M+10.3%
GOLDMAN SACHS GROUP INC
$9.69M+64.6%
Monaco Asset Management SAM
$8.48M+20.5%
GEODE CAPITAL MANAGEMENT, LLC
$8.11M+8.3%
FEDERATED HERMES, INC.
$7.88M+125.1%
JACOBS LEVY EQUITY MANAGEMENT, INC
$6.75M+374.1%
JPMORGAN CHASE & CO
$6.70M+149.7%
STATE STREET CORP
$6.22M-59.4%
DIMENSIONAL FUND ADVISORS LP
$3.85M+290.4%
MORGAN STANLEY
$3.63M-47.4%
Opaleye Management Inc.
$3.42M+4.7%
D. E. Shaw & Co., Inc.
$3.25M-56.2%
Jump Financial, LLC
$2.97M+82.1%
RENAISSANCE TECHNOLOGIES LLC
$2.71M+24.5%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$2.56M+3.4%
NORTHERN TRUST CORP
$2.51M+14.7%
See all 187 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/RCKT

Earnings Per Share

13fpro.ai/company/RCKT

Loading ratio trend…

RCKT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About ROCKET PHARMACEUTICALS, INC. (RCKT): stock profile, AI score and financials

ROCKET PHARMACEUTICALS, INC. (RCKT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RCKT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), ROCKET PHARMACEUTICALS, INC. reports net income of $123.2M, free cash flow of $-39.6M. Top institutional holders of RCKT by reported 13-F value include RTW INVESTMENTS, BlackRock, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. RCKT trades on the Nasdaq exchange and files with the SEC under CIK 1281895. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RCKT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ROCKET PHARMACEUTICALS, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1281895 →